CTOs on the Move

Merck Group

www.merckgroup.com

 
We are Merck, a vibrant science and technology company. Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create. The passion of our curious minds makes a positive difference to millions of people`s lives every day. In Healthcare, we discover unique ways to treat the most challenging diseases, such as multiple sclerosis and cancer. Our Life Science experts empower scientists by developing tools and solutions that help deliver breakthroughs more quickly. And in Electronics, we develop science that sits inside technologies and changes the way we access, store, process, and ...
  • Number of Employees: 10K-50K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Laura Matz
Chief Technology Officer Profile
Dirk Toepfer
Chief Information Officer Profile
Dirk Toepfer
Group Chief Information Officer and Head of Information Technology Profile

Similar Companies

Ajinomoto AminoScience

Ajinomoto AminoScience is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Javan and Walter

Javan and Walter, Inc is a Glen Burnie, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Abner Labs

Abner Innovation Laboratories Limited (“Abner Labs”) is a British Columbia, Canada, company formed to acquire Abner Technology Group Limited (“Abner Group”), owner of the ibetmobile sports viewing and betting technology platform. This proprietary, artificial intelligence (“AI”) driven smart technology makes watching and wagering on live sports on any online device as easy as playing video games.

The Ritedose Corporation,

  MANUFACTURING Philosophy The TRC team understands that the actions required to be a successful pharmaceutical manufacturer are more than just completing repetitive and highly detailed tasks accurately; it is the understanding that we...

Milestone Pharmaceuticals

Milestone was founded in 2005 with the underlying concept to base its drug development programs on clinically validated mechanisms of action in order to mitigate as much drug development risk as possible. The company has raised a total of $34 million in venture capital financing since 2006. At its founding, the company assembled a panel of leading pharmaceutical R&D executives (“drug hunters”) each with an average of 30 years experience in drug development. The drug hunters proposed NCE projects based on clinically proven science to form the basis of Milestone’s drug development programs. Milestone has a seasoned management team with experience in cardiovascular diseases, drug development and business start-ups as well as world-class advisory boards of key opinion leaders with significant expertise in cardiology, regulatory affairs, as well as formulation and drug development.